

## Transparency notification received from CPH Banque

### Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings

**Gosselies, Belgium, 24 December 2020, 7am CET – BONE THERAPEUTICS** (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 22 December 2020 indicating that the shareholdings held by CPH Banque have crossed above the threshold of 5% following the issuance of new shares of Bone Therapeutics via a private placement on 11 December 2020. The new shares were delivered to the participating investors on 16 December 2020.

The notification dated 22 December 2020 contains the following information:

- Reason for the notification: *Acquisition or disposal of voting securities or voting rights*
- Notification by: *A person that notifies alone*
- Person subject to the notification requirement: *CPH Banque*
- Transaction date: *16 December 2020*
- Threshold that is crossed: *5%*
- Denominator: *16,478,168*
- Notified details:

Voting rights	After the transaction	
	Holder of voting rights	# of voting rights
CPH Banque	1,333,333	8.09%

The notification can be consulted on the website of Bone Therapeutics, under the heading “*Shareholder Information*”.

### About Bone Therapeutics

*Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.*

*Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.*

*Bone Therapeutics' core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics' scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.*

*Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at [www.bonetherapeutics.com](http://www.bonetherapeutics.com).*

**For further information, please contact:**

**Bone Therapeutics SA**

Miguel Forte, MD, PhD, Chief Executive Officer  
Jean-Luc Vandebroek, Chief Financial Officer  
Tel: +32 (0)71 12 10 00  
[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)

For Belgian Media and Investor Enquiries:

**Bepublic**

Catherine Haquenne  
Tel: +32 (0)497 75 63 56  
[catherine@bepublic.be](mailto:catherine@bepublic.be)

International Media Enquiries:

**Image Box Communications**

Neil Hunter / Michelle Boxall  
Tel: +44 (0)20 8943 4685  
[neil.hunter@ibcomms.agency](mailto:neil.hunter@ibcomms.agency) / [michelle@ibcomms.agency](mailto:michelle@ibcomms.agency)

For French Media and Investor Enquiries:

**NewCap Investor Relations & Financial Communications**

Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé  
Tel: +33 (0)1 44 71 94 94  
[bone@newcap.eu](mailto:bone@newcap.eu)

For US Media and Investor Enquiries:

**LHA Investor Relations**

Yvonne Briggs  
Tel: +1 310 691 7100  
[ybriggs@lhai.com](mailto:ybriggs@lhai.com)

---

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*

---